SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split

January 2, 2024

https://www.globenewswire.com/news-release/2024/01/02/2802947/0/en/SAB-Biotherapeutics-Announces-1-for-10-Reverse-Stock-Split.html

SIOUX FALLS, S.D., Jan. 02, 2024 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a fully-human anti-thymocyte immunoglobulin (hIgG) for disease-modification of Type 1 Diabetes (T1D), today announced that it will effect a reverse stock split of its outstanding shares of common stock, effective as of 12:01 a.m. Eastern Time on January 5, 2024.

Read more at globenewswire.com

Related news for (SABS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.